Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy and Tolerance of Fractionated Radio-immunotherapy With 90Y-Epratuzumab (90Y-hLL2) for Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients

NCT01354457 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT01354457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01354457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy and Tolerance of Fractionated Radio-immunotherapy With 90Y-Epratuzumab (90Y-hLL2) for Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients
Lead sponsor
Nantes University Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 30, 2010
Completion date
June 30, 2016
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia